MIRA Pharmaceuticals, Inc. Other Income and Expense
MIRA Pharmaceuticals, Inc. (MIRA) reported Other Income and Expense of -$52.41 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-12
- MIRA Pharmaceuticals, Inc. nonoperating income (expense) for the quarter ending 2026-06-30 was -$52.41K, a 724.88% decline year-over-year.
- MIRA Pharmaceuticals, Inc. nonoperating income (expense) for the quarter ending 2026-03-31 was -$46.67K, a 317.88% decline year-over-year.
- MIRA Pharmaceuticals, Inc. nonoperating income (expense) for the quarter ending 2025-12-31 was -$158.49K, a 515.94% decline year-over-year.
- MIRA Pharmaceuticals, Inc. nonoperating income (expense) for the quarter ending 2025-09-30 was $179.31K, a 374.97% increase year-over-year.
- MIRA Pharmaceuticals, Inc. nonoperating income (expense) for fiscal 2025 was $50.63K, a 69.44% decline from fiscal 2024.
- MIRA Pharmaceuticals, Inc. nonoperating income (expense) for fiscal 2024 was $165.67K.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$52.41K 10-Q · filed 2026-08-12 | -$99.09K 10-Q · filed 2026-08-12 | -$257.58K derived: sum of 3 quarters · filed 2026-08-12 | -$78.27K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$46.67K 10-Q · filed 2026-05-14 | -$205.17K derived: sum of 2 quarters · filed 2026-05-14 | -$25.86K derived: sum of 3 quarters · filed 2026-05-14 | -$17.47K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$158.49K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $20.82K derived: sum of 2 quarters · filed 2026-03-31 | $29.21K derived: sum of 3 quarters · filed 2026-08-12 | $50.63K 10-K · filed 2026-03-31 |
| 2025-09-30 | $179.31K 10-Q · filed 2025-11-13 | $187.70K derived: sum of 2 quarters · filed 2026-08-12 | $209.12K 10-Q · filed 2025-11-13 | $247.23K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $8.39K 10-Q · filed 2026-08-12 | $29.81K 10-Q · filed 2026-08-12 | $67.91K derived: sum of 3 quarters · filed 2026-08-12 | $105.67K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $21.42K 10-Q · filed 2026-05-14 | $59.53K derived: sum of 2 quarters · filed 2026-05-14 | $97.28K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $38.10K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $75.86K derived: sum of 2 quarters · filed 2026-03-31 | $165.67K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $37.75K 10-Q · filed 2025-11-13 | $127.56K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |